Updated version 1 - Seres Company's cancer vaccine extends patient survival in blood cancer clinical trials
路透社2026/11/17 12:26Supplemented with stock performance and related details
Reuters, November 17 - Sellas Life Sciences (SLS.O) said on Tuesday that its experimental vaccine helped prolong survival for certain blood cancer patients in a late-stage clinical trial.
The vaccine, called galinpepimut-S (abbreviated as GPS), was tested in patients with acute myeloid leukemia, a rapidly growing cancer of the blood and bone marrow.
Sellas said that patients who received GPS had a median survival of 24 months, compared with 14.7 months for patients receiving the current best available treatments.
The company plans to discuss regulatory approval for the vaccine with the U.S. Food and Drug Administration (FDA). Its shares were halted in premarket trading.
(To assist those whose first language is not English, Reuters has automated the translation of its report into several other languages. Automated translation may be inaccurate or fail to capture required context, and Reuters does not guarantee the accuracy of the automated translation. The automated translation is provided solely for the convenience of readers. Reuters does not accept any liability for any damages or losses arising from the use of the automated translation feature.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Moody's: Downgrades NVIDIA outlook

Chris Vermeulen warns of deeper market selloff, sees gold falling to $3,100
Why the Unexpectedly Strong Earnings Report Couldn't Save Nvidia
Report: The European Central Bank plans to discuss raising the minimum reserve requirement from 1% to 2%
According to media reports, the European Central Bank’s Governing Council plans to discuss raising the minimum reserve requirement from the current 1% to 2% at its meeting on November 25. This move could save at least 4.4 billion euros annually for the ECB and 21 national central banks in the euro area, while also absorbing some of the excess liquidity in the system.